Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 772 • 2019 ACR/ARP Annual Meeting
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Shoko Tsuji¹, Hidenori Matsuzaki ², Masanori Iseki ³, Akiko Nagasu ¹, Hiroyasu Hirano ¹, Katsuhiko Ishihara ⁴, Naoyasu Ueda ⁵, Yoshitaka Honda ⁶, Takahiko Horiuchi ⁷, Ryuta Nishikomori ⁸, Yoshitaka Morita ¹ and Tomoyuki Mukai ⁹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, shobara, Hiroshima, Japan, ³Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Immunology and Molecular Genetics, Kurashiki, Okayama, Japan, ⁵Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, ⁶Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁸Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan, ⁹Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan
Background/Purpose: TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in the TNFRSF1A gene. Although more than…
Abstract Number: 785 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Muhammad Shipa¹, Anastasia-vasiliki Madenidou ², vera Choida ¹, Anna Radziszewska ³, corinne fisher ⁴, coziana ciurtin ¹, maria Leandro ¹ and Debajit Sen ¹, ¹Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, ²Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom
Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
Abstract Number: 929 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
Stanley Cohen¹, Katie Tuckwell ², Rebecca Kunder ², Tamiko Katsumoto ³, Rui Zhao ², Alberto Berman ⁴, Nemanja Damjanov ⁵, Dmytro Fedkov ⁶, Slawomir Jeka ⁷ and Mark Genovese ³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Genentech, Inc., South San Francisco, CA, ³Stanford University, Stanford, CA, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁶Bohomolets National Medical University, Kyiv, Ukraine, ⁷University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an orally administered, highly selective, non-covalent, and reversible small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK).1 We report the efficacy…
Abstract Number: 947 • 2019 ACR/ARP Annual Meeting
TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2
Ryan Laird¹, Patrycja Hoffmann ², Karyl Barron ², Deborah Stone ², Michele Nehrebecky ³, Anne Jones ², Tina Romeo ², Camilo Toro ³, Arianne Soldatos ⁴, Cornelia Cudrici ³, Daniel Kastner ² and Amanda Ombrello ², ¹National Institues of Health, Bethesda, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, ⁴NIH/NINDS, Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by biallelic loss-of-function mutations in the ADA2 gene . Over 60 pathogenic…
Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Yannick Degboe ¹, Flavia Sunzini ¹, Iain McInnes ² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…
Abstract Number: 1871 • 2013 ACR/ARHP Annual Meeting
Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains
Jinlong Jian¹, Shuai Zhao¹, Qingyun Tian¹, Elena Gonzalez Gugel², Jyoti Mundra², Sardar MZ Uddin², Ben Liu³, Brendon Richbourgh², Ryan Brunetti², Gerald Chan⁴, Carolyn Green⁵ and Chuanju Liu¹, ¹Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, ²NYU Hospital for Joint Diseases, New York, NY, ³NYU Hospital for Joint Diseases, New York Univerity, NY, ⁴Atreaon, Boston, MA, ⁵Atreaon, Boston, NY
Background/Purpose: We previously reported that Progranulin (PGRN) bound to TNF receptors (TNFR) and was therapeutic in inflammatory arthritis (Tang, W., et al, Science, 2011). PGRN…
Abstract Number: 1365 • 2012 ACR/ARHP Annual Meeting
Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁸ and Nathan Vastesaeger⁹, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp and Dohme, Kenilworth, NJ, ⁹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Efficacy of anti–tumor necrosis factor (TNF) therapy in patients with axial spondyloarthritis (SpA) has been tested only in patients who are refractory to NSAIDs.…
Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial
Anita Kåss¹, Øystein T. Førre², Morten Fagerland³, Hans Christian Gulseth⁴, Peter Torjesen⁵ and Ivana Hollan⁶, ¹University of Oslo, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Biostatistics, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Betanien Hospital, Skien, Norway, ⁵Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁶Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…
Abstract Number: 779 • 2012 ACR/ARHP Annual Meeting
Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁹ and Nathan Vastesaeger¹⁰, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp & Dohme, Kenilworth, NJ, ⁹Merck Sharp and Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Few studies have evaluated changes in active inflammation of spine and sacroiliac (SI) joints by MRI during long-term treatment for axial SpA, and no…
Abstract Number: 549 • 2012 ACR/ARHP Annual Meeting
A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁹ and Nathan Vastesaeger¹⁰, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp & Dohme, Kenilworth, NJ, ⁹Merck Sharp and Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives:…
Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Bernard Combe¹, Bhaskar Dasgupta², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, Ruji Yao¹⁰, Nathan Vastesaeger¹¹ and Holly Weng¹⁰, ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰Merck Sharp & Dohme, Kenilworth, NJ, ¹¹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…
Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Bhaskar Dasgupta¹, Bernard Combe², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, W. Bensen¹⁰, V. Wolff¹¹, Ruji Yao¹², Holly Weng¹² and Nathan Vastesaeger¹³, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ¹¹Hospital del Salvador, Santiago, Chile, ¹²Merck Sharp & Dohme, Kenilworth, NJ, ¹³Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].